Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie Inc    ABBV

ABBVIE INC (ABBV)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
04/21/2017 04/24/2017 04/25/2017 04/26/2017 04/27/2017 Date
63.82(c) 64.66(c) 65.1(c) 65.04(c) 66.6 Last
4 154 869 7 120 988 5 352 864 5 008 927 5 082 282 Volume
+0.06% +1.32% +0.68% -0.09% +2.40% Change
More quotes
Financials ($)
Sales 2017 27 722 M
EBIT 2017 11 880 M
Net income 2017 7 284 M
Debt 2017 26 035 M
Yield 2017 3,97%
Sales 2018 30 258 M
EBIT 2018 13 659 M
Net income 2018 8 926 M
Debt 2018 22 570 M
Yield 2018 4,35%
P/E ratio 2017 14,15
P/E ratio 2018 11,72
EV / Sales2017 4,68x
EV / Sales2018 4,17x
Capitalization 103 646 M
More Financials
Company
AbbVie, Inc. is a research-based biopharmaceutical company.It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products.The company focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Surperformance© ratings of AbbVie Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE INC
04:24p ABBVIE INC (NYSE : ABBV) reported earnings of $1.28 per share beating Walls Stre..
01:56p ABBVIE INC. (NYSE : ABBV) Files An 8-K Results of Operations and Financial Condi..
01:48p ABBVIE : tops Street 1Q forecasts
01:44p ABBVIE INC. : Results of Operations and Financial Condition, Financial Statement..
01:39p ABBVIE : Reports First-Quarter 2017 Financial Results
12:25p PFIZER : Novartis, Pfizer and Amgen top pharma`s lobby spending in eventful Q1
04/26 PFIZER : Aquinnah Pharmaceuticals Receives $10M Investment from Pfizer and Abbvi..
04/26 PFIZER : Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer an..
04/24 ABBVIE : HCV/ compensated cirrhosis drug achieved 99% SVR12 rate
04/21 ABBVIE INC : Blog Coverage AbbVie's HCV Regimen Achieves 99% Cure Rate in Phase ..
More news
Sector news : Specialty & Advanced Pharmaceuticals
10:10aDJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue -- Update
09:41aDJASTRAZENECA : Correction to AstraZeneca Profit Drops on Decline in Blockbuster-D..
09:26aDJBAYER : First-Quarter Net Profit Up 38% at EUR2.08 Billion -- Update
08:48aDJGLAXOSMITHKLINE : New Glaxo CEO Seeks Tighter Drug Focus -- WSJ
08:45aDJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on ABBVIE INC 
2015A likely recovery
More Strategies
Latest Tweets
03:55p$ABBV W1 view IHS for pattern traders  
03:50pAbbVie stock surges 1.5% after first-quarter profit, revenue beats: Marketwat.. 
03:49p$ABBV D1 open pull back then rip higher -  
03:43p$ABBV: AbbVie beats by $0.02, reports revs in-line; reaffirms FY17 EPS guidan.. 
02:48pDrugmaker AbbVie's profit and revenue beat as sales of a key drug rose
1
More tweets
Qtime:173
News from SeekingAlpha
08:04a AbbVie Q1 top line up 10%; Humira sales up 15%; V Pak sales down 37%; earning..
07:39a AbbVie beats by $0.02, beats on revenue
04/26 S&P 500 'Safer' Dividend Dogs Topped By Macy's & Qualcomm Per Analyst Upsides..
04/26 Notable earnings before Thursday?s open
04/26 S&P 500 'Safer' Dividend Aristocrats See Air Products In Top 3 For Gains, Per..
Advertisement
Chart ABBVIE INC
Duration : Period :
AbbVie Inc Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Full-screen chart
Technical analysis trends ABBVIE INC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 71,2 $
Spread / Average Target 9,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC3.96%103 646
MERCK KGAA7.97%15 200
KYOWA HAKKO KIRIN CO L..17.18%9 824
JAZZ PHARMACEUTICALS P..44.68%9 468
CONVATEC GROUP PLC32.11%7 743
ZHANGZHOU PIENTZEHUANG..24.18%4 974
More Results